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AIM To determine the validity of the proposed clinical diagnostic criteria for anti-N-methyl-Daspartate receptor (NMDAR) encephalitis in paediatric patients.
METHOD
The diagnostic criteria for anti-NMDAR encephalitis proposed by Graus et al. (2016) use clinical features and conventional investigations to facilitate early immunotherapy before antibody status is available. The criteria are satisfied if patients develop four out of six symptom groups within 3 months, together with at least one abnormal investigation (electroencephalography/cerebrospinal fluid) and reasonable exclusion of other disorders. We evaluated the validity of the criteria using a retrospective cohort of paediatric patients with encephalitis. Twenty-nine patients with anti-NMDAR encephalitis and 74 comparison children with encephalitis were included.
RESULTS
As expected, the percentage of patients with anti-NMDAR encephalitis who fulfilled the clinical criteria increased over time. During the hospital inpatient admission, most patients (26/29, 90%) with anti-NMDAR encephalitis fulfilled the criteria, significantly more than the comparison group (3/74, 4%) (p<0.001). The median time of fulfilling the criteria in patients with anti-NMDAR encephalitis was 2 weeks from first symptom onset (range [1] [2] [3] [4] [5] [6] . The sensitivity of the criteria was 90% (95% confidence interval 73-98) and the specificity was 96% (95% confidence interval 89-99).
INTERPRETATION The proposed diagnostic criteria for anti-NMDAR encephalitis have good sensitivity and specificity. Incomplete criteria do not exclude the diagnosis.
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a severe but treatable encephalitis which is increasingly recognized in young individuals. The definite diagnosis of anti-NMDAR encephalitis relies on the demonstration of anti-NMDAR antibodies in cerebrospinal fluid (CSF) in patients with a compatible clinical picture. However, there is often a delay in NMDAR antibody testing, even in resource-rich countries. Furthermore, antibody testing is not readily accessible in many parts of the world, particularly resource-poor countries. In view of this, Graus et al. developed diagnostic criteria for autoimmune encephalitis solely based on neurological assessment and conventional investigations. 1 This approach aimed to allow a prompt 'suspected diagnosis', and allow early initiation of immunotherapy while awaiting NMDAR antibody results, with the hope of achieving better clinical outcomes. Our study evaluated the validity of the diagnostic criteria for anti-NMDAR encephalitis in children.
METHOD
According to Graus et al., the diagnosis of probable anti-NMDAR encephalitis can be made when all three of the proposed criteria have been met. 1 The first criterion is rapid onset (<3mo) of at least four out of six major groups of clinical symptoms, including: (1) abnormal (psychiatric) behaviour or cognitive dysfunction; (2) speech dysfunction (pressured speech, verbal reduction, mutism); (3) seizures; (4) movement disorders, dyskinesias, or rigidity/abnormal postures; (5) decreased level of consciousness; and (6) autonomic dysfunction or central hypoventilation. The second criterion is the presence of at least one of the following laboratory study results: either (1) abnormal electroencephalogram (EEG) (focal or diffuse slow or disorganized activity, epileptic activity, or extreme delta brush) or (2) CSF with pleocytosis or oligoclonal bands. The third criterion is reasonable exclusion of other disorders. All three criteria should be fulfilled for a probable diagnosis of anti-NMDAR encephalitis.
The criteria were tested using an established cohort of children (younger than 16y of age) with encephalitis from the Children's Hospital at Westmead, Sydney, Australia. The clinical features and investigation findings were retrieved from patients' notes as reported in Pillai et al. 2 To increase the cohort of patients with anti-NMDAR encephalitis, we also included data on children with anti-NMDAR encephalitis from Starship Children's Hospital, Auckland, New Zealand. 3 The clinical data were retrieved from the case notes by three clinicians in Sydney (ACCH, SSM, SCP) and two clinicians in Auckland (RH, HJ) with consensus agreement on clinical features and timing of acquisition of clinical features. Clinical data in 27 out of 29 patients with anti-NMDAR encephalitis were collected before generation and publication of the criteria by Graus et al. The presence of clinical symptoms was reported as positive only when there was clear documentation for at least 24 hours' duration. 2 All patients had EEG and CSF studies performed. CSF pleocytosis was defined as a CSF white cell count of at least 5 per microlitre.
In total, 29 patients with encephalitis with anti-NMDAR antibodies detected in CSF or serum (CSF positive=23, serum only tested=6) were included in the study. Twentyfive of the 29 patients with anti-NMDAR encephalitis received immune therapy during their inpatient admission (steroids n=25, intravenous immunoglobulin n=20, plasma exchange n=7, rituximab n=9, cyclophosphamide n=2, other n=2).
To determine the specificity of the criteria, 74 patients with other causes of encephalitis (35 cases of acute disseminated encephalomyelitis, 20 cases of enterovirus encephalitis, eight cases of herpes simplex virus encephalitis, and 11 cases of mycoplasma encephalitis) were used as a comparison group. The patients with herpes simplex virus encephalitis only had a monophasic course and did not have a biphasic course as seen in herpes simplex virus encephalitis followed by anti-NMDAR encephalitis. Fiftysix out of 74 of the encephalitis comparison group had serum NMDAR antibody testing and were negative. Aetiologies of encephalitis were defined according to criteria proposed by Granerod et al. and the results were published before the start of the current study. 2, 4 Cases were classified as confirmed, probable, or possible. Confirmed cases were based on detection of the organism or antibody in CSF or brain. Cases were defined as probable if there was serological evidence of acute infection or antibody production. Possible cases were based on detection of the organism from a specimen sample outside the central nervous system (such as throat, stool, etc.). 4 The hierarchical classification for the aetiologies and demographics is presented in Table I .
To investigate the validity of the diagnostic criteria during evolution of the disease, the criteria were applied to each patient during the hospital inpatient admission (anti-NMDAR encephalitis mean 75d, median 62, range 11-222; and control encephalitis mean 16d, median 11, range 1-160). All patients and children in the comparison group were improving at the time of discharge and had not evolved new clinical problems when seen at outpatient follow-up. The timing (in terms of weeks since first symptom onset) when the criteria were fulfilled (when appropriate) was recorded. The sensitivity and specificity were calculated using three, four, and five out of six symptom groups as thresholds. Fisher's exact test was used to compare different variables. The study was approved by the Ethics Committee of The Children's Hospital at Westmead (09/ CHW/56) and the Starship Children's Hospital.
RESULTS
As anticipated, the patients with anti-NMDAR encephalitis accrued symptoms over time, with 24% fulfilling Graus et al. criteria after 1 week of symptoms and 48% after 2 weeks of symptoms (Fig. 1a) . During the hospital inpatient admission, the median number of symptom domains (maximum six) present in the anti-NMDAR encephalitis • The median time of fulfilling the criteria in patients with anti-NMDAR was 2 weeks from first symptom onset.
group was five (range three to six), while that in the comparison group was two (range one to five). Regarding investigations, all patients with anti-NMDAR encephalitis had either an abnormal EEG (25/29, 86%) or an abnormal CSF (25/29, 86%). During the hospital inpatient admission, 26 out of 29 (90%) of the anti-NMDAR encephalitis group, and three out of 74 (4%) of the comparison group fulfilled the Graus et al. criteria (p<0.001). The symptom distribution of the 26 patients with anti-NMDAR encephalitis who fulfilled the criteria during the hospital inpatient admission is presented in Figure 1b ; psychiatric features and movement disorders were the most common, while speech dysfunction and autonomic features were the least common. The three patients in the anti-NMDAR encephalitis group who did not fulfil the diagnostic criteria were CSF-positive for anti-NMDAR antibody. The median time for fulfilling the criteria in patients with anti-NMDAR encephalitis was 2 weeks from first symptom onset (range 1-6) (Fig. 1a) . The three children from the comparison group who fulfilled the criteria included one patient with confirmed enterovirus encephalitis and two patients with probable mycoplasma encephalitis (all three were confirmed negative for serum anti-NMDAR antibody; brief case descriptions are given in Appendix S1, online supporting information). The sensitivity of the proposed diagnostic criteria during the hospital admission was 90% (95% confidence interval 73-98) and the specificity was 96% (95% confidence interval 89-99). The sensitivity and specificity of the criteria using three and five symptom groups as cut-offs are presented in Table II . 
DISCUSSION
Our inclusion criteria used the Granerod encephalitis criteria, as these are applicable to both our anti-NMDAR encephalitis and comparison encephalitis subgroups. Our study demonstrated that the diagnostic criteria for anti-NMDAR encephalitis proposed by Graus et al. have reasonably high sensitivity (90%) and specificity (96%). However, clinicians should be aware that not fulfilling the Graus et al. criteria does not exclude the possibility of anti-NMDAR encephalitis, as shown in three of our patients with anti-NMDAR encephalitis who were CSF NMDAR antibody-positive but who did not fulfil the criteria. Graus et al. note that clinical suspicion of autoimmune encephalitis in the very young child may be more challenging. Only three of our patients were younger than 2 years of age, and we agree it will be potentially more challenging to identify language, behaviour, and autonomic symptoms in such very young pre-verbal children. Moreover, it is worth noting that anti-NMDAR encephalitis is characterized by gradual evolution of symptoms, and most of our patients did not satisfy the criteria during the first week of symptoms. In our cohort, the median time for fulfilling the criteria was 2 weeks from first symptom onset (range 1-6), which is reassuring that using these clinical criteria will not result in significant delay. As evidenced by a large cohort study and a systematic review, early initiation of immune therapy is an independent predictor of good outcome in patients with anti-NMDAR encephalitis. 5, 6 Therefore, the diagnostic criteria are clinically important in guiding treatment in the early stage of disease before antibody status is available.
The practice of NMDAR antibody testing is likely to vary around the world. In some centres with easy and speedy access to NMDAR antibody testing, clinicians will probably test many patients with unexplained encephalopathy or neuropsychiatric syndromes with a low pretest probability. By contrast, in resource-poor countries, testing may need to be rationalized or may be impossible. In these countries, the criteria of Graus et al. may be highly important, and the sensitivity and specificity resulting from our study are reassuring. We also analysed how three or five clinical criteria affect the sensitivity and specificity. As anticipated, three clinical criteria had a lower specificity, whereas five clinical criteria had a lower sensitivity. These findings suggest that four clinical criteria are an appropriate cut-off, with reasonably high levels of both sensitivity and specificity. Although our findings support the utility of the Graus et al. criteria as a clinical tool, it is not our recommendation to wait until four clinical criteria are fulfilled before testing for NMDAR antibody or treating with immune therapy; instead, we would recommend starting immune therapy as soon as autoimmune encephalitis is considered possible.
Patients with acute disseminated encephalomyelitis, enterovirus encephalitis, herpes simplex virus encephalitis, and mycoplasma encephalitis were selected for the comparison group because they are common causes of infectious and immune-mediated encephalitis in children in our locality (Australia and New Zealand), and they present the most challenging differential diagnoses of anti-NMDAR encephalitis. The three children in the comparison group who fulfilled the Graus et al. clinical criteria had confirmed enterovirus encephalitis (n=1) and probable mycoplasma encephalitis (n=2). Although all three were serum NMDAR antibody-negative, it would have been useful to test CSF NMDAR antibody, particularly given the previously proposed description of anti-NMDAR encephalitis following mycoplasma infection. 7 Although the sensitivity and specificity in our study were promising, the usefulness of the diagnostic criteria in differentiating anti-NMDAR encephalitis from other causes of infectious encephalitis like Japanese B encephalitis (which is more common in Asia and known to have prominent movement disorders) requires further evaluation. Children with other aetiologies of acute encephalopathy such as metabolic, toxic, or vascular causes were not recruited to the comparison group since most of these acute encephalopathy syndromes can be excluded by careful history and targeted investigations.
The patients with anti-NMDAR encephalitis and those in the comparison group included in our study were retrieved from our existing database. The clinical symptoms were recorded, and the aetiologies of those in the comparison group were determined and published for 27 out of 29 patients with anti-NMDAR encephalitis before designing this study, therefore potentially reducing bias. 2, 3 As might be expected, the median and mean duration of inpatient admission was longer for the patients with anti-NMDAR encephalitis than for the comparison group, although all individuals were improving at the time of discharge and had not evolved new clinical problems when seen at outpatient follow-up. A limitation of our study was that not all children in the comparison group were tested for NMDAR antibody, although all fulfilled confirmed, probable, or possible diagnoses (acute disseminated encephalomyelitis, enterovirus, etc.) using international consensus criteria. 2, 8 Testing of patients with rare encephalitic syndromes or even 'unknown' encephalitis could also have improved our study. We acknowledge that criterion 3 of Graus et al., ('reasonable exclusion of other disorders') lacks specificity and may differ according to clinical variables; however, a list of differential diagnoses of autoimmune encephalitis is available in the supplementary material of Graus et al., 1 to guide clinicians in the application of criterion 3.
CONCLUSION
The proposed clinical diagnostic criteria for anti-NMDAR encephalitis have high sensitivity and specificity. Paediatricians may use the criteria to guide immunotherapy before the antibody status is available.
